Bei Patienten mit Migräne sind Medikamente oft ein wichtiger Auslöser

Arne Vielitz

DOI: https://doi.org/10.1055/a-1220-0785

2020-09-01

manuelletherapie

Abstract:Diener HC, Antonaci F, Braschinsky M et al. European Academy of Neurology Guideline on the Management of Medication-Overuse Headache. Eur J Neurol 2020; 27: 1102–1116. doi: 10.1111/ene.14268

What problem does this paper attempt to address?

Neues aus der Akuttherapie der Migräne

Axel Heinze,Katja Heinze-Kuhn,Hartmut Göbel,Carl H Göbel

DOI: https://doi.org/10.1055/a-2331-0716

2024-06-14

Fortschritte der Neurologie · Psychiatrie

Abstract:Die Landschaft der Akutmedikation der Migräne hat sich in den vergangenen Jahren grundlegend verändert. Es ist ein schleichender, vielfach unbemerkter Prozess, der weniger durch die spektakuläre Einführung neuer Substanzen geprägt ist, als vielmehr durch die Veränderung des Zuganges der Patienten zu den Substanzen und die differenzierte Auswahl der Behandlung angepasst an die Bedürfnisse der Patienten. Inzwischen sind in Deutschland vier Triptane rezeptfrei verfügbar mit großem Einfluss auf die Selbstmedikation. Die wesentliche Neueinführung war das Lasmiditan als Alternative zu den Triptanen. The landscape of acute migraine medication has changed fundamentally in recent years. It has been a gradual, often unnoticed process characterized less by spectacular introduction of new substances than by changes in patients' access to medications and individualized selection of treatment adapted to the patients' needs. Four triptans are now available over-the-counter in Germany which has a major influence on self-medication. The main new introduction was the 5HT1F-agonist lasmiditan as an alternative to triptans. Received: 09 October 2023 Accepted after revision: 15 May 2024 Article published online: 12 June 2024 © 2024. Thieme. All rights reserved. Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany

psychiatry,clinical neurology
New migraine drugs: A critical appraisal of the reason why the majority of migraine patients do not receive an adequate medication

Hans Christoph Diener,Arne May

DOI: https://doi.org/10.1177/03331024241228605

2024-03-25

Cephalalgia

Abstract:Cephalalgia, Volume 44, Issue 3, March 2024. The last three decades have produced several novel and efficient medications to treat migraine attacks and reduce attack frequency. Additionally, promising approaches for the development of acute therapy and migraine prophylaxis continue to be pursued. At the same time as we witness the development of better and more efficient medications with continuously fewer side effects, we also realise that the high cost of such therapies means that only a minority of migraine patients who could benefit from these medications can afford them. Furthermore, information on cost-effectiveness is still lacking. Here, we compare availiable data, highlight open questions and suggest trials to close knowledge gaps. With good reason, our medicine is evidence-based. However, if this evidence is not collected, our decisions will continue to be based on marketing and assumptions. At the moment, we are not doing justice to our patients.

neurosciences,clinical neurology
Kopfschmerz bei Medikamentenübergebrauch

Steffen Naegel

DOI: https://doi.org/10.1055/a-2332-5973

2024-07-19

Fortschritte der Neurologie · Psychiatrie

Abstract:Der Kopfschmerz durch Medikamentenübergebrauch (MOH) ist eine weltweit verbreitete und beeinträchtigende Erkrankung, die durch übermäßige Einnahme von Akuttherapie entsteht und die Lebensqualität erheblich beeinträchtigen kann und das obwohl z.B. einfache Informationen über Ursachen und Folgen der Erkrankung dazu beitragen können, den MOH zu verhindern oder zu beenden. In den letzten Jahren konnten viele neue Erkenntnisse zum Kopfschmerz durch Medikamentenübergebrauch generiert werden. Zudem haben sich die Diagnosekriterien und die Leitlinienempfehlungen umfassend gewandelt. Dieser Artikel bietet einen umfassenden Überblick über die Klinik, Definition/Klassifikation, Epidemiologie, Risikofaktoren, Pathophysiologie, Kontroversen, Prävention und Behandlung des MOH. Medication overuse headache (MOH) is a globally prevalent and debilitating condition that results from excessive use of acute therapies and can significantly affect quality of life, despite the fact that simple information about the causes and consequences of the condition can help prevent or stop MOH. In recent years, many new insights have been gained into headaches caused by medication overuse. In addition, the diagnostic criteria and guideline recommendations have changed considerably. This article provides a comprehensive overview of the clinic, definition/classification, epidemiology, risk factors, pathophysiology, controversies, prevention, and treatment of MOH. Received: 20 November 2023 Accepted after revision: 15 May 2024 Article published online: 18 July 2024 © 2024. Thieme. All rights reserved. Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany

psychiatry,clinical neurology
Acute medications' intake for migraine: a one-year report in patients undergoing first evaluation at a third level Italian headache center

Adriano Bonura,Alessandro Alesina,Elisabetta Sapio,Nicoletta Brunelli,Marilena Marcosano,Claudia Altamura,Fabrizio Vernieri

DOI: https://doi.org/10.3389/fneur.2024.1450039

2024-08-29

Abstract:Background: Headache disorders, particularly primary headaches like migraine and tension-type headache, still remain underdiagnosed and undertreated despite their high prevalence and significant impact on quality of life. In recent years, several specific medications targeting key pathways in the pathophysiology of migraine have been developed. Despite this advancement, numerous studies indicate that non-steroidal anti-inflammatory drugs (NSAIDs) and analgesics remain the most commonly used drugs. This study focused on the use of NSAIDs and simple analgesics as acute treatments for migraine among patients at a tertiary headache center. Methods: A retrospective observational study was conducted at the Fondazione Policlinico Universitario Campus Bio-Medico throughout 2022. Data were collected on the type and frequency of headaches, the usage and dosage of NSAIDs and other medications, and changes in their use at follow-up visits. Statistical analyses were performed to evaluate the efficacy and determinants of NSAID consumption and headache frequency changes. Results: Two hundred and eightythree patients diagnosed with migraine undergoing their first examination at our center were enrolled. Initially, 58.7% of patients used NSAIDs or simple analgesics, which decreased to 46.6% 3 months after, while triptan use increased from 65.1 to 72.8%. Changes in prophylactic therapies were significantly associated with a decrease in NSAID intake (W = 834.000, p = 0.004) and in headache frequency (W = 5960.5, p = 0.003). Specifically, the addition of topiramate or amitriptyline was associated with a reduction in NSAID use and headache frequency. Even pain freedom after the intake of NSAIDs improved from 55.2 to 79.4% of cases at follow-up. Conclusion: The study highlights the importance of appropriate diagnosis and tailored treatment strategies in the management of primary headaches. It underscores the need for specialized care to enhance treatment efficacy and patient outcomes, demonstrating that adjustments in prophylactic therapy can significantly reduce NSAID intake and improve headache care. This reinforces the role of tertiary headache centers in providing specialized care that can adapt treatments to individual patient needs and improve overall headache management.
Acute migraine in the Emergency Department: extending European principles of management

Paolo Martelletti,Ivano Farinelli,Timothy J. Steiner,

DOI: https://doi.org/10.1007/s11739-008-0188-1

2008-09-11

Internal and Emergency Medicine

Abstract:The World Health Organization (WHO) placed migraine 19th among all causes of disability (12th in women) measured in years of healthy life lost to disability (YLD). The importance of headache disorders, particularly of the primary forms, is established by their distribution worldwide, their duration (the majority being life-long conditions) and their imposition of both disability and life-style restrictions among large numbers of people. For these reasons, headache disorders should represent a public-health priority. In the Emergency Department (ED), as elsewhere, migraine is often under-diagnosed—and under-treated when it is diagnosed. The result is likely to be failure of treatment. Particular attention to diagnosis is needed in ED patients with acute headache, since there is a higher probability of secondary headache due to underlying pathologies. According to European principles of management, acute migraine treatment generally is stepwise. Of the two main steps, the first relies on symptomatic medication, preferably NSAIDs with or without antiemetics. The second step uses specific therapies, usually triptans. Modifications to routine practice are appropriate in the ED. Parenteral administration of symptomatic therapies is a preferred first choice, whilst immediate resort to triptans may be appropriate, and achieve better outcomes, in patients with severe headache and diagnostic confirmation of migraine.

medicine, general & internal
Pharmacological management of migraine: current strategies and future directions

Lanfranco PellesiThien Phu DoAnders Hougaarda Clinical Pharmacology,Pharmacy and Environmental Medicine,Department of Public Health,University of Southern Denmark,Odense,Denmarkb Department of Neurology,Copenhagen University Hospital – Rigshospitalet,Copenhagen,Denmarkc Department of Neurology,Danish Knowledge Center on Headache Disorders,Glostrup,Denmarkd Department of Clinical Medicine,Faculty of Medical and Health Sciences,University of Copenhagen,Copenhagen,Denmarke Department of Neurology,Copenhagen University Hospital - Herlev and Gentofte,Herlev,Denmark

DOI: https://doi.org/10.1080/14656566.2024.2349791

2024-05-09

Expert Opinion on Pharmacotherapy

Abstract:Introduction Migraine is a complex neurological disorder that affects a significant portion of the global population. As traditional pharmacological approaches often fall short in alleviating symptoms, the development of innovative therapies has garnered significant interest. This text aims to summarize the current pharmacological options for managing migraine and to explore the potential impact of novel therapies.

pharmacology & pharmacy
Es tut sich viel in der Migräne- und Kopfschmerz-Therapie!

Dagny Holle-Lee,Claudia Sommer

DOI: https://doi.org/10.1055/a-2315-2100

2024-07-19

Fortschritte der Neurologie · Psychiatrie

Abstract:Kopfschmerzen, insbesondere Migräne, stellen eine der häufigsten neurologischen Erkrankungen dar, die das tägliche Leben von Millionen Menschen weltweit beeinträchtigen. Die letzten Jahre haben jedoch bedeutende Fortschritte in der Kopfschmerzmedizin gebracht, die Hoffnung und Erleichterung für viele Betroffene bieten. Die Entdeckung von Calcitonin-gene related peptide (CGRP) als eines der Schlüsselmoleküle in der Pathophysiologie der Migräne war ein bedeutender Schritt in der Entwicklung neuer Medikamente gegen Migräne und für das generelle Verständnis der Erkrankung. Article published online: 18 July 2024 © 2024. Thieme. All rights reserved. Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany

psychiatry,clinical neurology
Manual joint mobilisation techniques, supervised physical activity, psychological treatment, acupuncture and patient education in migraine treatment. A systematic review and meta-analysis

Dagmar Beier,Henriette E Callesen,Louise N Carlsen,Kirsten Birkefoss,Hanna Tómasdóttir,Hanne Wűrtzen,Henrik W Christensen,Lotte S Krøll,Mette Jensen,Christel V Høst,Jakob M Hansen

DOI: https://doi.org/10.1177/03331024211034489

2021-08-18

Cephalalgia

Abstract:Background Many people suffering from migraine combine pharmacological and non-pharmacological treatments. The purpose of this systematic review is to provide an updated guideline for some widely used non-pharmacological treatment options for migraine. Methods We conducted a systematic literature review of randomized studies of adults with migraine treated with manual joint mobilisation techniques, supervised physical activity, psychological treatment, acupuncture and patient education. The main outcomes measured were days with headache and quality of life. Recommendations were formulated based on the Grade of Recommendation, Assessment, Development and Evaluation (GRADE) approach including patient preferences based on expert opinion and questionnaire data. Results The overall level of certainty of the evidence was low to very low. Manual therapy techniques and psychological treatment did not change the studied outcomes. Supervised physical activity might have a positive impact on quality of life, acupuncture on headache frequency, intensity, quality of life and the use of attack-medicine. Patient education might improve self-rated health and quality of life and increase the number of well-informed patients. Conclusion Based on observed effects, the lack of serious adverse events, and patients’ preferences, we make weak recommendations for considering the investigated interventions as a supplement to standard treatment. Protocol registration: Prospero CRD42020220132.

neurosciences,clinical neurology
Hallmarks of primary headache: part 1 – migraine

Alberto Raggi,Matilde Leonardi,Marco Arruda,Valeria Caponnetto,Matteo Castaldo,Gianluca Coppola,Adriana Della Pietra,Xiangning Fan,David Garcia-Azorin,Parisa Gazerani,Lou Grangeon,Licia Grazzi,Fu-Jung Hsiao,Keiko Ihara,Alejandro Labastida-Ramirez,Kristin Sophie Lange,Marco Lisicki,Alessia Marcassoli,Danilo Antonio Montisano,Dilara Onan,Agnese Onofri,Lanfranco Pellesi,Mario Peres,Igor Petrušić,Bianca Raffaelli,Eloisa Rubio-Beltran,Andreas Straube,Sebastian Straube,Tsubasa Takizawa,Claudio Tana,Michela Tinelli,Massimiliano Valeriani,Simone Vigneri,Doga Vuralli,Marta Waliszewska-Prosół,Wei Wang,Yonggang Wang,William Wells-Gatnik,Tissa Wijeratne,Paolo Martelletti

DOI: https://doi.org/10.1186/s10194-024-01889-x

2024-11-01

The Journal of Headache and Pain

Abstract:Migraine is a common disabling conditions which, globally, affects 15.2% of the population. It is the second cause of health loss in terms of years lived with disability, the first among women. Despite being so common, it is poorly recognised and too often undertreated. Specialty centres and neurologists with specific expertise on headache disorders have the knowledge to provide specific care: however, those who do not regularly treat patients with migraine will benefit from a synopsis on the most relevant and updated information about this condition. This paper presents a comprehensive view on the hallmarks of migraine, from genetics and diagnostic markers, up to treatments and societal impact, and reports the elements that identify migraine specific features.

neurosciences,clinical neurology
Migräne in speziellen hormonellen Situationen

Sabine Segerer,Stefan Evers,Heike Israel-Willner,Bianca Raffaelli,Raffaelli,Bianca

DOI: https://doi.org/10.1055/a-2162-6004

2024-03-07

Geburtshilfe und Frauenheilkunde

Abstract:Welche Therapieoptionen gibt es bei menstrueller Migräne? Wie hilft man Patientinnen, die sowohl an Endometriose als auch an Migräne erkrankt sind, am besten? Was ist bei einer hormonellen Transition zu beachten? Der Beitrag gibt Empfehlungen zu Therapie und Prophylaxe. Article published online: 06 March 2024 © 2024. Thieme. All rights reserved. Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany

obstetrics & gynecology
Frequent Headaches: Evaluation and Management

Anne Walling

2020-04-01

Abstract:Most frequent headaches are typically migraine or tension-type headaches and are often exacerbated by medication overuse. Repeated headaches can induce central sensitization and transformation to chronic headaches that are intractable, are difficult to treat, and cause significant morbidity and costs. A complete history is essential to identify the most likely headache type, indications of serious secondary headaches, and significant comorbidities. A headache diary can document headache frequency, symptoms, initiating and exacerbating conditions, and treatment response over time. Neurologic assessment and physical examination focused on the head and neck are indicated in all patients. Although rare, serious underlying conditions must be excluded by the patient history, screening tools such as SNNOOP10, neurologic and physical examinations, and targeted imaging and other assessments. Medication overuse headache should be suspected in patients with frequent headaches. Medication history should include nonprescription analgesics and substances, including opiates, that may be obtained from others. Patients who overuse opiates, barbiturates, or benzodiazepines require slow tapering and possibly inpatient treatment to prevent acute withdrawal. Patients who overuse other agents can usually withdraw more quickly. Evidence is mixed on the role of medications such as topiramate for patients with medication overuse headache. For the underlying headache, an individualized evidence-based management plan incorporating pharmacologic and nonpharmacologic strategies is necessary. Patients with frequent migraine, tension-type, and cluster headaches should be offered prophylactic therapy. A complete management plan includes addressing risk factors, headache triggers, and common comorbid conditions such as depression, anxiety, substance abuse, and chronic musculoskeletal pain syndromes that can impair treatment effectiveness. Regular scheduled follow-up is important to monitor progress.
Medication-Overuse Headache: Update on Management

Prut Koonalintip,Katherine Phillips,Benjamin R. Wakerley

DOI: https://doi.org/10.3390/life14091146

2024-09-12

Life

Abstract:Long-term frequent use of acute pain medication for the treatment of headaches has paradoxically been shown to increase the frequency of headaches. So-called medication-overuse headache (MOH) is particularly problematic in patients with migraine who overuse triptans and opioids. Prevention through education remains the most important management strategy. Once established, MOH can be difficult to treat. Although complete or near-complete withdrawal of acute pain medication for 8–12 weeks has been shown to benefit most patients, this can be hard to achieve. The use of OnabotulinumtoxinA and drugs that target the calcitonin gene-related peptide system for the prevention of migraines have been shown to benefit patients with MOH. Furthermore, the use of novel acute pain medication for migraines, including Gepants and Ditans, which do not cause MOH, are likely to improve patient outcomes. In this review article we examine the following: the burden of MOH; who develops MOH; the pathophysiological mechanisms; and the treatment strategies.

biology
An update on migraine

Teddy Hervias

DOI: https://doi.org/10.1097/01.jaa.0000000000000014

2024-04-25

JAAPA

Abstract:ABSTRACT Migraine headache is a common and potentially debilitating disorder often treated by physician associates/assistants (PAs) and other providers. With the recent advances in new drugs and device technology for the treatment of migraine, the American Headache Society has released a consensus statement on both preventive and acute strategies for clinical practice. The US FDA has recently approved various types of medications and devices for the treatment and prevention of migraine attacks including several calcitonin gene-related peptide (CGRP) receptor inhibitors, a selective serotonin receptor agonist (SSRA), noninvasive vagus nerve stimulation (nVNS), external trigeminal nerve stimulation (e-TNS), and external concurrent occipital and trigeminal neurostimulation (eCOT-NS), among other pharmacologic and nonpharmacologic options. This article provides a review of migraine prevention and acute treatment protocol, highlighting new approaches to both.

medicine, general & internal
[Management of migraine by hospital emergency departments: a retrospective observational study carried out at the Hospital Universitario Virgen del Rocio]

N Sánchez-Rodríguez,M Millán-Vázquez,A Fernández-Panadero,A E Gómez-Caminero,C González-Oria

DOI: https://doi.org/10.33588/rn.7906.2024095

2024-09-16

Abstract:Introduction: Migraine is the second most common type of primary headache disorder in Europe, accounting for 2.8% of visits to emergency departments. Some studies have shown that emergency departments may approach the disorder in ways that may be insufficient or inadequate. Materials and methods: A retrospective observational study was conducted of patients with migraine who were discharged from the adult emergency department of the Hospital Universitario Virgen del Rocio in 2020. Variables related to their healthcare were analysed. Results: 73.9% were women, with a mean age of 38 years. They were not asked about the frequency of their migraines. The mean length of time patients spent in the emergency department before receiving initial medical care was 45 minutes (standard deviation: 41). Computed tomography scans were requested for 27.4% of the patients, and these were not pathological. Nonsteroidal anti-inflammatory drugs were the most commonly used treatment for the symptoms. Opioids were also used. Preventive treatments were prescribed in 6% of cases. Conclusions: Management of migraines by emergency departments is limited, and as such continuous and updated training is important. The use of triptans and occipital nerve blocks should be encouraged, and the use of opioids, among other drugs, should cease.
The Role of the Combination Paracetamol/Caffeine in Treatment of Acute Migraine Pain: A Narrative Review

Barbanti Piero,Allais Gianni,Cevoli Sabina,Guerzoni Simona,Valeriani Massimiliano,Vernieri Fabrizio

DOI: https://doi.org/10.1007/s40122-024-00581-x

IF: 3.96

2024-03-06

Pain and Therapy

Abstract:IntroductionThirty years ago, the first migraine-specific drugs (triptans) appeared. Today two new categories (gepants and ditans) are marketed for acute migraine treatment. That said, is there still a role for conventional therapy? The aim of the present narrative review is to provide an expert overview examining the possible role of the combination paracetamol/caffeine in treatment of acute migraine pain.MethodsTo understand possible settings for more appropriate use of paracetamol/caffeine (1000 mg/130 mg) in treatment of acute migraine, a structured literature search was performed using the PubMed database by a panel of experts from major Italian headache centers; articles not referring to migraine pain were excluded from this review; review articles were prioritized.ResultsOverall response, even to newer specific and selective trigeminal targeted drugs (TTTs), is not over 60%; thus, there is still room for conventional therapies in acute migraine treatment. The panel identified settings in which the use of paracetamol/caffeine combination to treat acute migraine attacks might offer benefit considering the consolidated use through years, despite the lack of studies directly addressing the efficacy of paracetamol/caffeine in the identified populations: subjects > 65 years of age; presence of cardiovascular (CV) comorbidities; TTTs non-responders; pregnancy and breastfeeding; subjects < 18 years of age; paracetamol/caffeine as add-on therapy.ConclusionsParacetamol is included in the World Health Organization (WHO) essential drug list and has a high level of popularity among patients. Caffeine enhances the analgesic effect of other drugs including paracetamol. In early treatment of acute migraine pain, prescribing physicians might consider using the paracetamol/caffeine combination among other options.

clinical neurology
Migräne und Hormonbehandlung

Sabine Segerer,Stefan Evers,Dagny Holle-Lee,Christoph Keck

DOI: https://doi.org/10.1055/a-2162-5870

2024-01-05

Geburtshilfe und Frauenheilkunde

Abstract:Eine Hormontherapie erhöht bekanntermaßen das Thrombembolierisiko. Migräne mit Aura erhöht bei Frauen unter 45 Jahren das Risiko für einen Schlaganfall um ca. das Doppelte. Zwei Fakten, die deutlich machen, dass bei Frauen mit Migräne, bei denen eine Hormontherapie indiziert ist, einiges zu beachten ist. Dieser Beitrag informiert u. a. über Vor- und Nachteile einer Hormongabe bei Migränepatientinnen in verschiedenen Lebensphasen. Article published online: 03 January 2024 © 2023. Thieme. All rights reserved. Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany

obstetrics & gynecology
Health care resource utilization and costs associated with diagnosed medication overuse headache and potential acute medication overuse in individuals with migraine

Anand R. Shewale,Jennifer A. Brandenburg,Kate Burslem,Richard B. Lipton,Jalpa A. Doshi

DOI: https://doi.org/10.1177/03331024241235139

2024-02-29

Cephalalgia

Abstract:Cephalalgia, Volume 44, Issue 2, February 2024. ObjectiveEstimate health care resource utilization and costs associated with medication overuse headache and potential acute medication overuse.MethodsA retrospective analysis was conducted with Clinformatics Data Mart data (1 January 2019–31 December 2019) that included continuously enrolled commercially insured adults with migraine (International Classification of Diseases, Tenth Revision, Clinical Modification [ICD-10-CM] code G43.xxx). Medication overuse headache was defined as ≥1 inpatient or ≥2 outpatient claims with an ICD-10-CM code G44.41/40 (drug-induced headache). Potential acute medication overuse was defined as possessing sufficient medication for >10 mean treatment days/month for ergots, triptans, opioids, or combination analgesics or >15 mean cumulative days/month for simple prescription analgesics (e.g., acetaminophen, aspirin, other non-opioid analgesics) for >6 consecutive months. All-cause and migraine-related health care resource utilization and costs were compared after adjusting for demographic and clinical characteristics.ResultsAmong 90,017 individuals with migraine, the frequency of medication overuse headache/potential acute medication overuse was 12.6% (diagnosed medication overuse headache: 0.6%; potential acute medication overuse: 12.1%). Adjusted all-cause total costs ( 21,486; difference: 9,770 vs 3,563 [P < 0.001]) were higher in the medication overuse headache/potential acute medication overuse group versus those without medication overuse headache/potential acute medication overuse.ConclusionsIndividuals with diagnosed medication overuse headache/potential acute medication overuse had higher all-cause and migraine-related health care resource utilization and costs versus individuals without medication overuse headache/potential acute medication overuse, suggesting that improved migraine management is needed to reduce associated costs.

neurosciences,clinical neurology
Clinical guidance for choosing the right pharmacotherapy for migraine attacks

Izabela Domitrz

DOI: https://doi.org/10.1080/14656566.2024.2303425

2024-01-11

Expert Opinion on Pharmacotherapy

Abstract:Introduction Migraine as headache attacks with autonomic symptoms is a serious condition and it is important to treat a single attack effectively in order to improve not only the patient's quality of life at a given moment but also to prevent the migraine from becoming a chronic one.

pharmacology & pharmacy
Migraine - a borderland disease to epilepsy: near it but not of it

Jakob Paungarttner,Martina Quartana,Lucrezia Patti,Barbora Sklenárová,Fatemeh Farham,Inés Hernando Jiménez,M. Gokcen Soylu,Irina Maria Vlad,Semih Tasdelen,Teresa Mateu,Oreste Marsico,Federica Reina,Viktoria Tischler,Christian Lampl,on behalf of the European Headache Federation School of Advanced Studies (EHF – SAS)

DOI: https://doi.org/10.1186/s10194-024-01719-0

2024-01-27

The Journal of Headache and Pain

Abstract:Migraine and epilepsy are two paroxysmal chronic neurological disorders affecting a high number of individuals and being responsible for a high individual and socioeconomic burden. The link between these disorders has been of interest for decades and innovations concerning diagnosing and treatment enable new insights into their relationship.

neurosciences,clinical neurology
Worldwide availability of medications for migraine and tension-type headache: A survey of the International Headache Society

Francesca Puledda,Irene de Boer,Roberta Messina,David Garcia-Azorin,Marcio Nattan Portes Souza,Mohammad Al-Mahdi Al-Karagholi,Olivia Begasse de Dhaem,Cristina Tassorelli,Arne May

DOI: https://doi.org/10.1177/03331024241297688

2024-11-27

Cephalalgia

Abstract:Cephalalgia, Volume 44, Issue 11, November 2024. BackgroundIn this study, we aimed to evaluate the differing global access to acute and preventive medications for migraine and tension-type headache.MethodsA custom-built questionnaire created by members of the International Headache Society Juniors Group was sent to International Headache Society members worldwide, including a list of acute and preventive treatments for migraine and tension-type headache. This list was based on evidence-based medicine guidelines. For each treatment, participants were asked about availability, type of reimbursement and variability of access within their country.ResultsEighty-four members completed the questionnaire providing data for 84 countries. The majority were neurologists (88%) and worked at an academic/university hospital (62%). Of participants, 36% were located in high-income economy countries and 13% were located in low-income economies. Common preventive treatments such as propranolol and topiramate were available in most countries (respectively in 99% and 92% of responding countries). Sumatriptan was available in most countries (95%), whereas other triptan availability was lower. Novel migraine treatments such as rimegepant and erenumab were only available in 14% and 46% of the assessed countries, respectively.ConclusionsAvailability of headache medications, ranging from simple analgesics to novel therapies migraine-specific drugs, varied greatly across the world. Actions are needed to improve effective drug availability in many countries to ensure an adequate management of people living with headache.

neurosciences,clinical neurology

Bei Patienten mit Migräne sind Medikamente oft ein wichtiger Auslöser

Neues aus der Akuttherapie der Migräne

New migraine drugs: A critical appraisal of the reason why the majority of migraine patients do not receive an adequate medication

Kopfschmerz bei Medikamentenübergebrauch

Acute medications' intake for migraine: a one-year report in patients undergoing first evaluation at a third level Italian headache center

Acute migraine in the Emergency Department: extending European principles of management

Pharmacological management of migraine: current strategies and future directions

Es tut sich viel in der Migräne- und Kopfschmerz-Therapie!

Manual joint mobilisation techniques, supervised physical activity, psychological treatment, acupuncture and patient education in migraine treatment. A systematic review and meta-analysis

Hallmarks of primary headache: part 1 – migraine

Migräne in speziellen hormonellen Situationen

Frequent Headaches: Evaluation and Management

Medication-Overuse Headache: Update on Management

An update on migraine

[Management of migraine by hospital emergency departments: a retrospective observational study carried out at the Hospital Universitario Virgen del Rocio]

The Role of the Combination Paracetamol/Caffeine in Treatment of Acute Migraine Pain: A Narrative Review

Migräne und Hormonbehandlung

Health care resource utilization and costs associated with diagnosed medication overuse headache and potential acute medication overuse in individuals with migraine

Clinical guidance for choosing the right pharmacotherapy for migraine attacks

Migraine - a borderland disease to epilepsy: near it but not of it

Worldwide availability of medications for migraine and tension-type headache: A survey of the International Headache Society